Dieter Volc

Vienna, 1180, Austria

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

A Case Report of a Novel Alpha-Synuclein Vaccine (TRB-001) in a Parkinson's Patient: Safe Administration and Induction of a High-Titer, High-Avidity Functional Antibody Response.

A Case Report of a Novel Alpha-Synuclein Vaccine (TRB-001) in a Parkinson's Patient: Safe Administration and Induction of a High-Titer, High-Avidity Functional Antibody Response.

Journal: Vaccines

Published: March 31, 2026

Three-Dimensional Screen Printing Technology Enables Sequential Release of Carbidopa and Levodopa-A New Approach Improving Levodopa Delivery for Treating Parkinson's Disease.

Three-Dimensional Screen Printing Technology Enables Sequential Release of Carbidopa and Levodopa-A New Approach Improving Levodopa Delivery for Treating Parkinson's Disease.

Journal: Pharmaceutics

Published: October 10, 2025

Comparing face-to-face and online LSVT®LOUD speech training using LSVT®Coach in patients with Parkinson's disease: a pilot randomised controlled trial.

Comparing face-to-face and online LSVT®LOUD speech training using LSVT®Coach in patients with Parkinson's disease: a pilot randomised controlled trial.

Journal: BMC neurology

Published: June 01, 2024

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.

Journal: Journal of Parkinson's disease

Published: June 07, 2021

A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.

A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: March 27, 2020

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.

Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson's disease: a randomised, single-blinded, phase 1 trial.

Journal: The Lancet. Neurology

Published: December 13, 2019

Sensor-based gait analysis of individualized improvement during apomorphine titration in Parkinson's disease.

Sensor-based gait analysis of individualized improvement during apomorphine titration in Parkinson's disease.

Journal: Journal of neurology

Published: May 13, 2018

Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease.

Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease.

Journal: Movement disorders : official journal of the Movement Disorder Society

Published: January 08, 2016

Showing 1-8 of 8

Last Updated: 09/26/2026